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The term punctate inner choroidopathy (PIC) was first used by Watzke et al. \[[@B1]\] in 1984 to describe findings in a group of patients with multifocal, well-circumscribed, small choroidal lesions.

PIC is an infrequent ocular inflammatory disease, mostly affecting young myopic women. Typically, patients present with symptoms of loss of central visual acuity, as well as photopsia and scotomata. Diagnosis was based on the visualization of multiple, small (between 100 and 300 μm), round, yellowish-white punctate lesions on fundoscopy, in the absence of ocular inflammation elsewhere in the eye (vitritis, pars planitis, anterior chamber cells or anterior synechiae) \[[@B1], [@B2]\]. These lesions appear to be located at the level of the choroid and the retinal pigment epithelium (RPE) and may coalesce and form a serous retinal detachment \[[@B1], [@B3]\].

Spectral-domain optical coherence tomography (SD-OCT) may be able to provide detailed structural characteristics of PIC lesions and may be a useful, noninvasive way of identifying disease activity in patients with PIC. Furthermore, Channa et al. \[[@B3]\] suggested that SD-OCT may provide information of disease activity that is not detected clinically or on fluorescein angiography (FA).

The lesions fill and stain during the late phase of FA. Autofluorescence images show hypofluorescence in cicatricial lesions and autofluorescence in active lesions \[[@B2]\].

PIC is usually a benign disease, with visual prognosis ordinarily favorable \[[@B4]\], but severe visual loss can occur if complicated by choroidal neovascularization (CNV) and subretinal fibrosis: rates of up to 69 and 56%, respectively, were reported \[[@B3]\]. These complications usually occur within 1 year of presentation \[[@B5]\]. Later, these lesions progress to hypopigmented, pigmented or hyperplastic fibrotic scars \[[@B2]\].

The management of CNV due to PIC has not been conclusively determined, so a variety of treatment options have been described: submacular surgery \[[@B6]\], laser photocoagulation, photodynamic therapy \[[@B4]\], immunosuppressants \[[@B7]\], intravitreal and systemic corticoids \[[@B8], [@B9]\] and intravitreal anti-VEGF agents \[[@B10], [@B11], [@B12]\].

Case Report {#sec1_2}
===========

A 29-year-old Caucasian male presented to our emergency department with complaints of decreased central vision in his left eye (LE), detected a few hours before. Ten years before, he had undergone ophthalmic surgery with phakic lens implantation due to high myopia in both eyes. The patient was taking benzodiazepines and beta-blockers due to panic disorder. He denied systemic disease known to be associated with choroiditis, systemic symptoms or recent illness. There was no relevant family history.

Best-corrected visual acuity (BCVA) in the LE was counting fingers at 50 cm. He described having blurred central vision in the LE tested on the Amsler grid. Fundoscopy of the LE evidenced multiple, round and yellowish lesions in the macula and nasal to the optic nerve, without signs of intraocular inflammation (fig. [1](#F1){ref-type="fig"}, left). BCVA in the right eye was 20/20, and ophthalmological examination showed slight changes of the RPE.

OCT showed increased retinal thickness with detachment of the neuroepithelium and a slight RPE detachment in the LE (fig. [1](#F1){ref-type="fig"}, middle). FA revealed hyperfluorescent lesions with blurred borders in the macula (fig. [1](#F1){ref-type="fig"}, right).

We performed a chest X-ray and an analytic study to exclude autoimmune and infectious diseases. Afterwards an intravitreal injection of bevacizumab (1.25 mg/0.05 ml) was administered in the LE, showing a significant reduction of the neuroepithelial detachment (fig. [2](#F2){ref-type="fig"}). Four months later, BCVA in the LE was 20/200 and no increased retinal thickness was seen on OCT.

One year later, the patient was reexamined and showed a BCVA of 20/40 in the LE. FA and OCT appearances confirmed no active lesions, and fundoscopy revealed a chorioretinal scar on papillomacular beam (fig. [3](#F3){ref-type="fig"}). The same findings were also observed 2 years later.
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PIC is more common in young, Caucasian females; nevertheless, it can occur among men, non-Caucasians and hyperopes \[[@B5]\]. We presented a case of a young, Caucasian and myopic male.

Essex et al. \[[@B13]\] found that, at the initial visit, 47% of patients had unilateral disease at baseline, with 77% of them having PIC lesions and CNV and 23% having PIC lesions only. On the other hand, Brown et al. \[[@B14]\] reported that 88% of patients with PIC had bilateral disease. Channa et al. \[[@B3]\] found that the majority of lesions (89%) in their study, irrespective of clinical activity, showed involvement of the RPE, including RPE elevation with sub-RPE signals and RPE discontinuity. Our patient presented with PIC lesions and CNV in the LE and also subtle RPE changes in the right eye.

It is known that PIC may lead to the development and growth of CNV. In recent years, studies analyzing the use of intravitreal anti-VEGF for treating CNV in PIC have been published and have shown good results \[[@B10], [@B12]\].

In our case report, one single injection of intravitreous bevacizumab produced anatomic and visual improvement. There was resolution of the serous retinal detachment after treatment, but there was no prompt restoration of BCVA. Interestingly, there was a considerable improvement of visual acuity 1 year after treatment.

Chan et al. \[[@B12]\] reported 4 patients with PIC treated with 3 injections of intravitreal bevacizumab. All improved and none had a BCVA of worse than 20/40 at final examination. Moreover, Leung et al. \[[@B15]\] reported a case of PIC complicated by CNV treated successfully with a single injection of intravitreal ranibizumab with no recurrence at 8 months.

Our patient showed no recurrence after 2 years of follow-up. Even though some authors used 3 monthly injections of anti-VEGF, we used only 1 injection with the purpose of administering additional injections as needed based on clinical examination and OCT.

Mangat et al. \[[@B11]\] proposed that due to the good visual outcomes and lack of complications, anti-VEGF treatment should be the first-line treatment in these cases. Furthermore, frequent follow-up for a long period to identify and treat any recurrence is recommended.

Frequently, patients who suffer from PIC have a delayed diagnosis \[[@B5]\]. Given that PIC could be associated with serious complications, such as CNV and subretinal fibrosis, mainly within the first year of disease, early diagnosis and close monitoring is beneficial in order to manage these complications promptly.
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